NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium
The state-of-the-art facility contains development and manufacturing space across multiple cleanrooms for the dedicated production of CGMP-grade pDNA for clinical and commercial-phase supply
Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies
The new Case Management Service addresses challenges associated with delivering advanced therapies to patients by providing supply chain oversight from program start to finish.
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
Mr. Zayas will be responsible for Catalent’s North American biologics operations. He will serve on the Executive Leadership Team, reporting directly to President & CEO, Alessandro Maselli.
Catalent and Ethicann Sign Agreement for New Cannabinoid-Based Treatments
Catalent and Ethicann announced a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet technology.
Sarepta and Catalent Expand Strategic Manufacturing Partnership
Catalent and Sarepta sign an agreement to manufacture delandistrogene moxeparvovec, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy.
Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina
Catalent today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Gosselies, Belgium
The new facility will be one of the largest in the world with multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing.
Catalent Completes Expansion of Clinical Supply Facility in Shanghai, China
The project has seen the site increase by approximately 30,000 square feet, which has allowed the installation of additional refrigerated and deep-frozen storage, and secondary packaging capabilities to be expanded.
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
The ADC candidates have been developed using Catalent’s proprietary SMARTag® technology.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.